REFERENCES
1. Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
2. Cabibbo G, Aghemo A, Lai Q, Masarone M, Montagnese S, Ponziani FR; Italian Association for the Study of the Liver (AISF). Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Dig Liver Dis. 2022;54:452-60.
3. Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020;72:2206-18.
4. Teufel A, Kudo M, Qian Y, et al. Current trends and advancements in the management of hepatocellular carcinoma. Dig Dis. 2024;42:349-60.
5. Vitale A, Cabibbo G, Iavarone M, et al; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22.
6. Kim KM, Sinn DH, Jung SH, et al. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016;36:1490-7.
7. Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62:440-51.
8. Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
9. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
10. Karnofsky D A. The clinical evaluation of chemotherapeutic agents in cancer. Eval Chemother Agents 1949:191-205. Available from: https://scispace.com/papers/the-clinical-evaluation-of-chemotherapeutic-agents-in-cancer-12buycduj2. [Last accessed on 11 Jul 2025].
11. Dolnikov S, Adam R, Cherqui D, Allard MA. Liver transplantation in elderly patients: what do we know at the beginning of 2020? Surg Today. 2020;50:533-9.
12. Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. In Vivo. 2019;33:1411-20.
13. Arora SP, Liposits G, Caird S, et al. Hepatocellular carcinoma in older adults: a comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol. 2020;11:557-65.
14. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-68.
15. VanWagner LB, Ning H, Whitsett M, et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score. Hepatology. 2017;66:1968-79.
16. Dick AA, Spitzer AL, Seifert CF, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl. 2009;15:968-77.
17. Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol. 2021;74:931-43.
18. Lai Q, Sapisochin G, Gorgen A, et al. Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant. JAMA Surg. 2021;156:e213112.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
20. Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl. 2007;13:1515-20.
21. Alaimo L, Endo Y, Lima HA, et al. A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score. J Gastrointest Surg. 2022;26:2486-95.
22. Chang YS, Huang JS, Yen CL et al. The Charlson comorbidity index is an independent prognostic factor for treatment-naïve hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology. 2015;62:1011-5.
23. Shinkawa H, Tanaka S, Takemura S, et al. Predictive value of the age-adjusted Charlson comorbidity index for outcomes after hepatic resection of hepatocellular carcinoma. World J Surg. 2020;44:3901-14.
24. Choi J, Choi EW, Choi Y, et al. Modified Charlson comorbidity index as a survival prediction tool for older patients after liver transplantation. Ann Surg Treat Res. 2023;104:358-63.
25. Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374-83.
26. Aliberti C, Carandina R, Lonardi S, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an italian center. J Vasc Interv Radiol. 2017;28:1495-502.
27. Farinati F, Vanin V, Giacomin A, et al; Italian Liver Cancer (ITA. LI.CA) group. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int. 2015;35:223-31.
28. Cabibbo G, Petta S, Barbara M, et al; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017;67:65-71.
29. Cabibbo G, Celsa C, Calvaruso V, et al; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265-73.
30. Celsa C, Cabibbo G, Fulgenzi CAM, et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment. Hepatology. 2025;81:837-52.
31. Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol. 2021;74:1225-33.
32. Cabibbo G, Celsa C, Battaglia S, et al. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death. Clin Cancer Res. 2025;31:543-50.
33. Reiberger T, Lens S, Cabibbo G, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81:326-44.
34. Piano S, Reiberger T, Bosch J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 2024;6:101233.
35. Wu J, Liu W, Qiu X, et al. A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma. Phenomics. 2023;3:549-64.
36. Fried LP, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.
37. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-544.
38. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:1870-9.
39. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66:564-74.
40. Tandon P, Reddy KR, O’Leary JG, et al; North American Consortium for the Study of End-Stage Liver Disease. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. Hepatology. 2017;65:217-24.
41. Tandon P, Tangri N, Thomas L, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. Am J Gastroenterol. 2016;111:1759-67.
42. Carey EJ, Steidley DE, Aqel BA, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16:1373-8.
43. Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol. 2017;23:899-905.
44. Dunn MA, Josbeno DA, Tevar AD, et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol. 2016;111:1768-75.
45. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166-73.
46. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015;6:e102.
47. Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;76:588-99.
48. Montano-Loza AJ. Skeletal muscle abnormalities and outcomes after liver transplantation. Liver Transpl. 2014;20:1293-5.
49. DiMartini A, Cruz RJ Jr, Dew MA, et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl. 2013;19:1172-80.
50. Kremer WM, Nagel M, Reuter M, et al. Validation of the clinical frailty scale for the prediction of mortality in patients with liver cirrhosis. Clin Transl Gastroenterol. 2020;11:e00211.
51. Bhanji RA, Narayanan P, Moynagh MR, et al. Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease. Liver Transpl. 2019;25:14-24.
52. Lai JC, Rahimi RS, Verna EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology. 2019;156:1675-82.
53. Essam Behiry M, Mogawer S, Yamany A, et al. Ability of the short physical performance battery frailty index to predict mortality and hospital readmission in patients with liver cirrhosis. Int J Hepatol. 2019;2019:8092865.
54. Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology. 2015;62:584-90.
55. Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. J Hepatol. 2018;69:818-25.
56. Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113:235-42.
57. Lai JC, Shui AM, Duarte-Rojo A, et al; from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study. Frailty, mortality, and health care utilization after liver transplantation: from the multicenter functional assessment in liver transplantation (FrAILT) study. Hepatology. 2022;75:1471-9.
58. Kardashian A, Ge J, McCulloch CE, et al. Identifying an optimal liver frailty index cutoff to predict waitlist mortality in liver transplant candidates. Hepatology. 2021;73:1132-9.
59. Lai JC, Dodge JL, Kappus MR, et al; Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020;73:575-81.
60. Wang M, Shui AM, Ruck J, et al. Clinically relevant cut-points for changes in the liver frailty index are associated with waitlist mortality in patients with cirrhosis. Liver Transpl. 2024;30:991-1001.
61. Wang M, Chiou SH, Ganger D, et al. Liver transplantation provides survival benefit at all levels of frailty: from the multicenter functional assessment in liver transplantation study. Hepatology. 2025;81:1269-75.
62. Yamada S, Shimada M, Morine Y, et al. Significance of frailty in prognosis after hepatectomy for elderly patients with hepatocellular carcinoma. Ann Surg Oncol. 2021;28:439-46.
63. Okada T, Tanaka S, Shinkawa H, et al. Impact of frailty on long-term outcomes after liver resection for hepatocellular carcinoma in elderly patients: a prospective study. Asian J Surg. 2024;47:147-53.
64. Yang T, Liu DQ, Qiu W, et al. The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: a multicenter cohort study. Am J Surg. 2024;237:115761.
65. Ramai D, Dang-Ho KP, Kewalramani A, et al. Hospital frailty risk score is independently associated with mortality and encephalopathy in hospitalized patients with hepatocellular carcinoma. Biomedicines. 2021;9:1693.
66. Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75 Suppl 1:S147-62.
67. Guo Y, Ren Y, Zhu L, Yang L, Zheng C. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis. Sci Rep. 2023;13:934.
68. Beumer BR, van Vugt JLA, Sapisochin G, et al; Collaborators. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. J Cachexia Sarcopenia Muscle. 2022;13:2373-82.
69. Cederholm T. Overlaps between frailty and sarcopenia definitions. Nestle Nutr Inst Workshop Ser. 2015;83:65-9.
70. Cruz-Jentoft AJ, Bahat G, Bauer J, et al; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31.
71. Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1611-44.
72. Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46:951-63.
73. Ii ER, Satapathy SK. Sarcopenia in the cirrhotic patient: current knowledge and future directions. J Clin Exp Hepatol. 2023;13:162-77.
74. Jiang C, Wang Y, Fu W, et al. Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis. Front Nutr. 2022;9:978110.
75. Liu J, Luo H, Huang L, Wang J. Prevalence of sarcopenia among patients with hepatocellular carcinoma: a systematic review and metaanalysis. Oncol Lett. 2023;26:283.
76. Nikolaou D. Sarcopenia and frailty: the detectable overlapping and the possible diagnostic approaches. JFSF. 2016;01:08-12.
77. Kichena S, Kamani A, Fricke B. Potential of prehabilitation in hepatocellular carcinoma: a narrative review of available evidence. Ann Palliat Med. 2024;13:101-11.
78. Stout NL, Santa Mina D, Lyons KD, Robb K, Silver JK. A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin. 2021;71:149-75.
79. Christopher CN, Kang DW, Wilson RL, et al. Exercise and nutrition interventions for prehabilitation in hepato-pancreato-biliary cancers: a narrative review. Nutrients. 2023;15:5044.
80. Marcantei C, Couret A, King J, Mazeaud S, Armand A, Ennequin G. Effects of exercise training on muscle mass and physical function in patients with hepatocellular carcinoma after diagnosis: a systematic review. Dig Dis Sci. 2024;69:2667-80.
81. Brustia R, Monsel A, Skurzak S, et al. Guidelines for perioperative care for liver transplantation: enhanced recovery after surgery (ERAS) recommendations. Transplantation. 2022;106:552-61.
82. Joliat GR, Kobayashi K, Hasegawa K, et al. Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations 2022. World J Surg. 2023;47:11-34.
83. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40:2898-913.
84. Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39:3533-62.
85. Toh EQ, Wong HPN, Wang JDJ, Liau MYQ, Tan YF, Shelat VG. Prehabilitation programs in liver resection: a narrative review. Chin Clin Oncol. 2024;13:9.
86. Jetten WD, Hogenbirk RNM, Van Meeteren NLU, Cuperus FJC, Klaase JM, De Jong R. Physical effects, safety and feasibility of prehabilitation in patients awaiting orthotopic liver transplantation, a systematic review. Transpl Int. 2022;35:10330.
87. Benmassaoud A, Martel M, Carli F, et al. Prehabilitation in patients awaiting liver transplantation. Transplant Rev. 2024;38:100835.
88. Loschi TM, Baccan MDTA, Della Guardia B, Martins PN, Boteon APCS, Boteon YL. Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review. World J Hepatol. 2023;15:1153-63.
89. Lin FP, Visina JM, Bloomer PM, et al. Prehabilitation-driven changes in frailty metrics predict mortality in patients with advanced liver disease. Am J Gastroenterol. 2021;116:2105-17.
90. Hallsworth K, McCain MV, Fallen-Bailey R, Brown MC, Orange ST, Reeves HL. Is home-based, virtually delivered, group exercise feasible and acceptable for older patients with hepatocellular carcinoma? A non-randomised feasibility study (TELEX-Liver Cancer). BMJ Open. 2024;14:e082155.
91. Colosimo S, Bertoli S, Saffioti F. Use of branched-chain amino acids as a potential treatment for improving nutrition-related outcomes in advanced chronic liver disease. Nutrients. 2023;15:4190.
92. Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, et al. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13:1440-52.
93. Espina S, Casas-Deza D, Bernal-Monterde V, Domper-Arnal MJ, García-Mateo S, Lué A. Evaluation and management of nutritional consequences of chronic liver diseases. Nutrients. 2023;15:3487.
94. Berardi G, Ratti F, Sposito C, et al. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. Hepatology. 2023;77:1527-39.
95. Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48:557-66.
96. Zhang Y, Zhan L, Zhang L, Shi Q, Li L. Branched-chain amino acids in liver diseases: complexity and controversy. Nutrients. 2024;16:1875.
97. van Dijk AM, Bruins Slot AS, Portincasa P, et al. Systematic review with meta-analysis: branched-chain amino acid supplementation in liver disease. Eur J Clin Invest. 2023;53:e13909.
98. Sideris GA, Tsaramanidis S, Vyllioti AT, Njuguna N. The role of branched-chain amino acid supplementation in combination with locoregional treatments for hepatocellular carcinoma: systematic review and meta-analysis. Cancers. 2023;15:926.
99. Chen L, Chen Y, Wang X, et al. Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J. 2015;14:67.
100. Yap KY, Chi H, Ng S, Ng DH, Shelat VG. Effect of perioperative branched chain amino acids supplementation in liver cancer patients undergoing surgical intervention: a systematic review. World J Gastrointest Surg. 2023;15:2596-618.
101. Wong CS, Praseedom R, Liau SS. Perioperative immunonutrition in hepatectomy: a systematic review and meta-analysis. Ann Hepatobiliary Pancreat Surg. 2020;24:396-414.
102. Gao B, Luo J, Liu Y, et al. Clinical efficacy of perioperative immunonutrition containing omega-3-fatty acids in patients undergoing hepatectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Nutr Metab. 2020;76:375-86.
103. Zhang C, Lin J, Li F, et al. Effect of ω-3 polyunsaturated fatty acids on liver function and inflammatory reaction in patients undergoing hepatectomy: a systematic review and meta-analysis of randomized control trials. Expert Rev Gastroenterol Hepatol. 2019;13:375-84.
104. Lei Q, Wang X, Zheng H, Bi J, Tan S, Li N. Peri-operative immunonutrition in patients undergoing liver transplantation: a meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2015;24:583-90.
105. Plank LD, Mathur S, Gane EJ, et al. Perioperative immunonutrition in patients undergoing liver transplantation: a randomized double-blind trial. Hepatology. 2015;61:639-47.
106. Ss S, Pottakkat B. Effect of immunonutrition on the liver function status of end-stage liver disease patients waiting/referred for liver transplant: a randomized controlled trial. Cureus. 2023;15:e36923.
107. Graf J, Stengel A. Psychological burden and psycho-oncological interventions for patients with hepatobiliary cancers-a systematic review. Front Psychol. 2021;12:662777.
108. Li L, Zhang HZ, Ge Y, et al. The perioperative experience and needs of hepatocellular carcinoma patients in interventional therapy: a phenomenological qualitative study. Eur J Gastroenterol Hepatol. 2024;36:423-9.
109. Wang J, Yan C, Fu A. A randomized clinical trial of comprehensive education and care program compared to basic care for reducing anxiety and depression and improving quality of life and survival in patients with hepatocellular carcinoma who underwent surgery. Medicine. 2019;98:e17552.
110. Zhang X, Lai M, Wu D, Luo P, Fu S. The effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery. Am J Transl Res. 2021;13:6638-45.
111. Grimmett C, Heneka N, Chambers S. Psychological interventions prior to cancer surgery: a review of reviews. Curr Anesthesiol Rep. 2022;12:78-87.
112. Delabays C, Demartines N, Joliat GR, Melloul E. Enhanced recovery after liver surgery in cirrhotic patients: a systematic review and meta-analysis. Perioper Med. 2024;13:24.
113. Noba L, Rodgers S, Chandler C, Balfour A, Hariharan D, Yip VS. Enhanced recovery after surgery (ERAS) reduces hospital costs and improve clinical outcomes in liver surgery: a systematic review and meta-analysis. J Gastrointest Surg. 2020;24:918-32.
114. Tinguely P, Morare N, Ramirez-Del Val A, et al. Enhanced recovery after surgery programs improve short-term outcomes after liver transplantation-a systematic review and meta-analysis. Clin Transplant. 2021;35:e14453.
115. Cillo U, Vitale A, Polacco M, Fasolo E. Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology. 2017;65:1741-8.
116. Cillo U, Vitale A, Volk ML, et al. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis. 2010;42:642-9.
117. European Association for the Study of the Liver. Electronic address: [email protected]. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-85.
118. Aduen JF, Sujay B, Dickson RC, et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc. 2009;84:973-8.
119. Su F, Yu L, Berry K, et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology. 2016;150:441-53.e6.
120. Gulla A, Jakiunaite I, Juchneviciute I, Dzemyda G. A narrative review: predicting liver transplant graft survival using artificial intelligence modeling. Front Transplant. 2024;3:1378378.
121. Romero-Cristóbal M, Díaz-Fontenla F, Fernández-Yunquera A, et al. Demographic trends in liver transplant survivors after 3 decades of program implementation: the impact of cohort and period effects on life expectancy. Transplant Direct. 2024;10:e1684.
122. Yong CM, Sharma M, Ochoa V, et al. Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation. Liver Transpl. 2010;16:1242-8.
123. Martinez-Perez S, McCluskey SA, Davierwala PM, et al. Perioperative cardiovascular risk assessment and management in liver transplant recipients: a review of the literature merging guidelines and interventions. J Cardiothorac Vasc Anesth. 2024;38:1015-30.
124. Pagano G, Sastre L, Blasi A, et al. CACS, CCTA and mCAD-LT score in the pre-transplant assessment of coronary artery disease and the prediction of post-transplant cardiovascular events. Liver Int. 2024;44:1912-23.
125. Alvarez J, Mei X, Daily M, et al. Tipping the scales: liver transplant outcomes of the super obese. J Gastrointest Surg. 2016;20:1628-35.
126. Cullaro G, Verna EC, Lee BP, Lai JC. Chronic kidney disease in liver transplant candidates: a rising burden impacting post-liver transplant outcomes. Liver Transpl. 2020;26:498-506.
127. Soldera J, Corso LL, Rech MM, et al. Predicting major adverse cardiovascular events after orthotopic liver transplantation using a supervised machine learning model: a cohort study. World J Hepatol. 2024;16:193-210.
128. Abdelhameed A, Bhangu H, Feng J, et al. Deep learning-based prediction modeling of major adverse cardiovascular events after liver transplantation. Mayo Clin Proc Digit Health. 2024;2:221-30.
129. Mancuso A, Mazzola A, Cabibbo G, et al. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis. 2015;47:324-30.
130. Bang K, Casadei-Gardini A, Yoo C, et al. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Med. 2023;12:2572-9.
131. Cillo U, Carraro A, Avolio AW, et al; Italian Board of Experts in Liver Transplantation (I-BELT). Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT). Updates Surg. 2024;76:725-41.
132. Kaibori M, Yoshii K, Yokota I, et al; Liver Cancer Study Group of Japan. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg. 2019;269:692-9.
133. Tan LLY, Chew VTW, Syn N, et al. Effect of age on the short- and long-term outcomes of patients undergoing curative liver resection for HCC. Eur J Surg Oncol. 2022;48:1339-47.
134. Okinaga H, Yasunaga H, Hasegawa K, Fushimi K, Kokudo N. Short-term outcomes following hepatectomy in elderly patients with hepatocellular carcinoma: an analysis of 10,805 septuagenarians and 2,381 Octo- and Nonagenarians in Japan. Liver Cancer. 2018;7:55-64.
135. Lee JS, Park DA, Ryoo S, Park J, Choi GH, Yoo JJ. Efficacy and safety of surgical resection in elderly patients with hepatocellular carcinoma: a systematic review and meta-analysis. Gut Liver. 2024;18:695-708.
136. Lu Y, Liang L, Lu WF, et al. The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis. Clin Res Hepatol Gastroenterol. 2023;47:102147.
137. Cauchy F, Zalinski S, Dokmak S, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 2013;100:113-21.
138. Viganò L, Conci S, Cescon M, et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol. 2015;63:93-101.
139. Berardi G, Cucchetti A, Sposito C, et al. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome. JHEP Rep. 2024;6:101075.
140. Molinari M, Kaltenmeier C, Samra PB, et al. Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients. Ann Surg Open. 2021;2:e065.
141. Lanari J, Lupi A, Billato I, et al. Textbook outcome and nomogram-guided approaches for enhancing surgical success in elderly HCC patients: deciphering the influence of sarcopenia. Updates Surg. 2024;76:2645-54.
142. Polvieng T, Hongjinda S, Thienhiran A, Burasakarn P, Fuengfoo P. Effect of sarcopenia on the prognosis of clinical outcomes in patients with hepatocellular carcinoma after hepatic resection. Am Surg. 2024;90:1447-55.
143. Kobayashi A, Kaido T, Hamaguchi Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg. 2019;269:924-31.
144. Giakoustidis A, Papakonstantinou M, Chatzikomnitsa P, et al. The effects of sarcopenia on overall survival and postoperative complications of patients undergoing hepatic resection for primary or metastatic liver cancer: a systematic review and meta-analysis. J Clin Med. 2024;13:3869.
145. Gani F, Cerullo M, Amini N, et al. Frailty as a risk predictor of morbidity and mortality following liver surgery. J Gastrointest Surg. 2017;21:822-30.
146. Tanaka S, Ueno M, Iida H, et al. Preoperative assessment of frailty predicts age-related events after hepatic resection: a prospective multicenter study. J Hepatobiliary Pancreat Sci. 2018;25:377-87.
147. Osei-Bordom D, Hall L, Hodson J, et al. Impact of frailty on short-term outcomes after laparoscopic and open hepatectomy. World J Surg. 2022;46:2444-53.
148. Voron T, Tselikas L, Pietrasz D, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg. 2015;261:1173-83.
149. Berardi G, Antonelli G, Colasanti M, et al. Association of sarcopenia and body composition with short-term outcomes after liver resection for malignant tumors. JAMA Surg. 2020;155:e203336.
150. Marasco G, Dajti E, Serenari M, et al. Sarcopenia predicts major complications after resection for primary hepatocellular carcinoma in compensated cirrhosis. Cancers. 2022;14:1935.
151. Snowden CP, Prentis JM, Anderson HL, et al. Submaximal cardiopulmonary exercise testing predicts complications and hospital length of stay in patients undergoing major elective surgery. Ann Surg. 2010;251:535-41.
152. Carli F, Scheede-Bergdahl C. Prehabilitation to enhance perioperative care. Anesthesiol Clin. 2015;33:17-33.
153. Yu Q, Liu C, Navuluri R, Ahmed O. Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Abdom Radiol. 2021;46:4467-75.
154. South E, Wade R, Anwer S, et al. The effectiveness of ablative and non-surgical therapies for early hepatocellular carcinoma: systematic review and network meta-analysis of randomised controlled trials. Cancer Med. 2023;12:20759-72.
155. Cillo U, Bertacco A, Fasolo E, et al. Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: results of 815 procedures. J Surg Oncol. 2019;120:956-65.
156. Cillo U, Noaro G, Vitale A, et al; HePaTIC Study Group. Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. HPB. 2014;16:979-86.
157. Gerges FJ, Kanazi GE, Jabbour-Khoury SI. Anesthesia for laparoscopy: a review. J Clin Anesth. 2006;18:67-78.
158. Hoffmann R, Rempp H, Schmidt D, Pereira PL, Claussen CD, Clasen S. Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol. 2012;23:545-51.
159. Skonieczki BD, Wells C, Wasser EJ, Dupuy DE. Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: is it safe? Eur J Radiol. 2011;79:343-6.
160. Ibrahim SM, Lewandowski RJ, Sato KT, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14:1664-9.
161. Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40:468-80.
162. He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953-60.
163. Fründt TW, Casar C, von Felden J, et al. Equal efficacy and safety profile in elderly patients with hepatocellular carcinoma receiving palliative treatment. Cancers. 2022;14:768.
164. Tang Q, Huang W, Liang J, Xue J. Efficacy and safety of transarterial chemoembolization in elderly patients of advanced hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Front Oncol. 2021;11:646410.
165. Sun Z, Jiao D, Fang Y, et al. Efficacy and safety of raltitrexed-eluting CalliSpheres® bead transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma: a single-arm, prospective study. Ther Adv Med Oncol. 2024;16:17588359241229661.
166. Schindler P, Kaldewey D, Rennebaum F, et al. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis. J Cancer Res Clin Oncol. 2024;150:235.
167. Zhang L, Hong W, Wang Z, Zheng C, Liang B, Shi H. Safety and effectiveness of transarterial chemoembolization in hepatocellular carcinoma patients aged greater versus less than 80 years. Clin Interv Aging. 2023;18:1883-92.
168. Lin WC, Chang CW, Chang CW, Wang TE, Chen MJ, Wang HY. Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease. Medicine. 2019;98:e17007.
169. Hsu CY, Huang YH, Su CW, et al. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol. 2010;44:e171-7.
170. Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: pathophysiology, prognosis, and treatment challenges. World J Gastroenterol. 2021;27:4104-42.
171. Giannini EG, Aglitti A, Borzio M, et al; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers. 2019;11:1689.
172. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317-45.
173. Vogel A, Martinelli E; ESMO Guidelines Committee. Electronic address: [email protected]; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801-5.
174. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960-74.
175. Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments. Dig Liver Dis. 2024;56:394-405.
176. Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65:1140-7.
177. Vithayathil M, D’Alessio A, Fulgenzi CAM, et al. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. Liver Int. 2022;42:2538-47.
178. Hajiev S, Allara E, Motedayеn Aval L, et al. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer. 2021;124:407-13.
179. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30:446.
180. Li D, Toh HC, Merle P, et al. Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the imbrave150 randomized clinical trial. Liver Cancer. 2022;11:558-71.
181. Alkadimi MA, Aldawoodi TA, Lucero KT, et al. Clinical characteristics, treatment patterns, and outcomes of patients with locally advanced/metastatic hepatocellular carcinoma treated at the veterans health administration. Oncologist. 2024;29:369-76.
182. Song BG, Goh MJ, Kang W, et al. Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. Gut Liver. 2024;18:709-18.
183. Carballo-Folgoso L, Álvarez-Velasco R, Lorca R, et al. Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver Int. 2021;41:2200-11.
184. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20-8.
185. Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019;13:248-52.
186. Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36:1905-12.
187. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904-11.
